04:34 PM EDT, 06/03/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday that 45% of patients with locally advanced or metastatic solid tumors getting TransCon IL-2 every three weeks in the phase 1/2 clinical trial showed clinical response.

The company said as of the April 16 data cutoff, two of the five patients with anti-PD-1 refractory melanoma in the phase 2 dose-escalation cohort, who received TransCon IL-2 in combination with TransCon TLR7/8 Agonist, had confirmed clinical responses.

No new safety signals were observed in patients getting TransCon IL-2 alone or in combination with pembrolizumab or TransCon TLR7/8 Agonist, and the treatments were well tolerated, according to Ascendis.

Price: 135.16, Change: -0.15, Percent Change: -0.11